TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30275398

Group type: EXPERIMENTAL
Intervention: Nutritional supplementation combined with cognitive stimulation (fortified milk powder and daily learning activities)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Unfortified milk powder (control group)
Number of subjects: 0
Study: 28072453

Group type: EXPERIMENTAL
Intervention: Abstainers at 6 months
Number of subjects: 1061

Group type: EXPERIMENTAL
Intervention: Low-risk drinkers at 6 months
Number of subjects: 1061

Group type: COMPARATOR
Intervention: Heavy drinkers at 6 months
Number of subjects: 1061

Group type: EXPERIMENTAL
Intervention: Abstainers and low-risk drinkers at 6 months
Number of subjects: 1061

Group type: EXPERIMENTAL
Intervention: Low-risk drinkers and abstainers
Number of subjects: 1061
Study: 25527746

Group type: EXPERIMENTAL
Intervention: Bariatric surgery
Number of subjects: 2010

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 2010
Study: 23142798

Group type: EXPERIMENTAL
Intervention: Withania somnifera (2 g every 8 hours during chemotherapy)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Chemotherapy alone (control group)
Number of subjects: 100
Study: 21620782

Group type: EXPERIMENTAL
Intervention: Target inhalation mode (TIM)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Tidal breathing mode (TBM)
Number of subjects: 20
Study: 18464021

Group type: EXPERIMENTAL
Intervention: Estetrol 0.1 mg
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Estetrol 1 mg
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Estetrol 10 mg
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Estetrol 100 mg
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 17320009

Group type: EXPERIMENTAL
Intervention: SMART BAG resuscitator
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional bag-valve-mask (Easy Grip) resuscitator
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both devices
Number of subjects: 0
Study: 14967156

Group type: EXPERIMENTAL
Intervention: Capillary plasma glucose measurements
Number of subjects: 350

Group type: COMPARATOR
Intervention: Venous plasma glucose measurements
Number of subjects: 350
Study: 11237274

Group type: EXPERIMENTAL
Intervention: Severe Traumatic Brain Injury Outcome Interview
Number of subjects: 0

Group type: COMPARATOR
Intervention: Glasgow Outcome Scale
Number of subjects: 0

Group type: COMPARATOR
Intervention: Disability Rating Scale
Number of subjects: 0
Study: 9210746

Group type: EXPERIMENTAL
Intervention: Monthly maintenance interpersonal psychotherapy with placebo (N = 19)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo and supportive medication clinic without interpersonal psychotherapy (N = 28)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Maintenance interpersonal psychotherapy (N = 9)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Medication clinic without interpersonal psychotherapy (N = 12)
Number of subjects: 47
Study: 7955992

Group type: EXPERIMENTAL
Intervention: Cigarette smoking (determined by history and urine cotinine levels)
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Cigarette smoking
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Mean HbA1c during follow-up
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Mean HbA1c since diagnosis
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Mean blood pressure, lipoprotein(a), and apolipoprotein B
Number of subjects: 169
Study: 3297482

Group type: EXPERIMENTAL
Intervention: Neo Sampoon vaginal tablets (60 mg menfegol)
Number of subjects: 349

Group type: COMPARATOR
Intervention: Emko vaginal foam (8.0% nonoxynol-9)
Number of subjects: 349
Study: 31086947

Group type: EXPERIMENTAL
Intervention: Escherichia coli-produced bivalent HPV-16/18 vaccine
Number of subjects: 7372

Group type: COMPARATOR
Intervention: Control (hepatitis E vaccine)
Number of subjects: 7372
Study: 26810047

Group type: EXPERIMENTAL
Intervention: Pictorial mnemonic-strategy approach
Number of subjects: 8

Group type: COMPARATOR
Intervention: Children's own preferred learning methods
Number of subjects: 8
Study: 26799126

Group type: EXPERIMENTAL
Intervention: Patient self-testing (PST)
Number of subjects: 2922

Group type: COMPARATOR
Intervention: Usual ACC care
Number of subjects: 2922
Study: 25618966

Group type: EXPERIMENTAL
Intervention: Dendritic cells (DCs) plus ginseng polysaccharides (GPS) administered thoracoscopically, once a week, 4 times for 30 days.
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control group treated with dendritic cells (DCs) alone.
Number of subjects: 96
Study: 23778443

Group type: EXPERIMENTAL
Intervention: Driving Simulator (DS)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 40
Study: 20453655

Group type: EXPERIMENTAL
Intervention: Terlipressin (2 mg bolus injection)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 18624605

Group type: EXPERIMENTAL
Intervention: Adaptation exercise (encouraged to consider their ability to adapt)
Number of subjects: 1117

Group type: COMPARATOR
Intervention: No adaptation exercise (control group)
Number of subjects: 1117
Study: 16652085

Group type: EXPERIMENTAL
Intervention: Oral prednisone for 2 weeks followed by intranasal budesonide for 12 weeks (Group A, n = 63)
Number of subjects: 84

Group type: COMPARATOR
Intervention: No steroid treatment (Group B, n = 21)
Number of subjects: 84
Study: 12651643

Group type: EXPERIMENTAL
Intervention: Liberalized fasting (Group L): formula fasted for 4-6 hours before surgery
Number of subjects: 97

Group type: COMPARATOR
Intervention: Traditional fasting (Group T): clear liquids up to 2 hours and formula fasted for 8 hours
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Both groups (L and T)
Number of subjects: 97
Study: 10092561

Group type: EXPERIMENTAL
Intervention: Regular weekly aerobic training programme, three times a week for 12 months
Number of subjects: 124

Group type: COMPARATOR
Intervention: Matched controls who did not receive any formal exercise training
Number of subjects: 124
Study: 7743718

Group type: EXPERIMENTAL
Intervention: Oxygen 41 min‐1 by Hudson mask during the procedure
Number of subjects: 29

Group type: COMPARATOR
Intervention: Air (Control)
Number of subjects: 29
Study: 2749124

Group type: EXPERIMENTAL
Intervention: Sodium benzoate
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Tartrazine
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Sodium metabisulfite
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo (lactose)
Number of subjects: 33
Study: 971031

Group type: EXPERIMENTAL
Intervention: Methylphenidate hydrochloride
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Thioridazine hydrochloride
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Methylphenidate/thioridazine combination
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30885839

Group type: EXPERIMENTAL
Intervention: Intravenous dexamethasone (Group A)
Number of subjects: 315

Group type: EXPERIMENTAL
Intervention: Intralesional dexamethasone (Group B)
Number of subjects: 315

Group type: COMPARATOR
Intervention: Oral dexamethasone (Group C)
Number of subjects: 315
Study: 28789469

Group type: EXPERIMENTAL
Intervention: Intensive, play-based leg activity with weights for the affected leg and foot, 1 hour/day, 4 days/week for 12 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care (not explicitly detailed)
Number of subjects: 0
Study: 26964161

Group type: EXPERIMENTAL
Intervention: Fire needle treatment
Number of subjects: 60

Group type: COMPARATOR
Intervention: Acupuncture treatment
Number of subjects: 60
Study: 23394792

Group type: EXPERIMENTAL
Intervention: LED phototherapy
Number of subjects: 40

Group type: COMPARATOR
Intervention: Laser acupuncture
Number of subjects: 40
Study: 21828109

Group type: EXPERIMENTAL
Intervention: Brushing the pleura (Group A)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Instillation of minocycline (Group B)
Number of subjects: 84
Study: 19519910

Group type: EXPERIMENTAL
Intervention: Enteral Nutrition (EN)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Enteral Nutrition combined with Parenteral Nutrition (EN + PN)
Number of subjects: 17
Study: 17966180

Group type: EXPERIMENTAL
Intervention: Intense pulsed light (IPL) device (Lumenis One)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Advanced fluorescent technology pulsed light (AFT, Harmony System)
Number of subjects: 8
Study: 15124680

Group type: EXPERIMENTAL
Intervention: Rituximab combined with chemotherapy
Number of subjects: 0
Study: 11269475

Group type: EXPERIMENTAL
Intervention: Individualized heparin dose calculated by an in vitro heparin dose‐response test (group HC)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Standard dose of heparin (300 IU/kg; group C)
Number of subjects: 26
Study: 9886723

Group type: EXPERIMENTAL
Intervention: Candoxatril (100 mg twice daily)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study: 8290176

Group type: EXPERIMENTAL
Intervention: Exercise alone (N = 25)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogen (0.625 mg) (N = 28)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Exercise supplemented with conjugated equine estrogen (N = 28)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Control (sedentary) (N = 20)
Number of subjects: 101
Study: 3569737

Group type: EXPERIMENTAL
Intervention: Omeprazole 10 mg/d (Om10)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg/d (Om20)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 12
Study: 30032884

Group type: EXPERIMENTAL
Intervention: Nebulised midazolam 0.2 mg kg‐1 (Group M)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Nebulised dexmedetomidine 2 μg kg‐1 (Group D)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Nebulised ketamine 2 mg kg‐1 (Group K)
Number of subjects: 90
Study: 26908681

Group type: EXPERIMENTAL
Intervention: MOC program participation
Number of subjects: 27
Study: 23895199

Group type: EXPERIMENTAL
Intervention: Functional labeling
Number of subjects: 410

Group type: EXPERIMENTAL
Intervention: Social labeling
Number of subjects: 410

Group type: COMPARATOR
Intervention: No label of previous donation (control condition)
Number of subjects: 410
Study: 22508621

Group type: EXPERIMENTAL
Intervention: Prophylactic swallowing exercises
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (no prophylactic exercises)
Number of subjects: 26
Study: 20360183

Group type: EXPERIMENTAL
Intervention: Topical NSAID
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Oral NSAID
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 18241283

Group type: EXPERIMENTAL
Intervention: Lansoprazole (L15)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Omeprazole (O10)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Omeprazole (O20)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Pantoprazole (P40)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: All PPIs
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Omeprazole (O20) and Pantoprazole (P40)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Lansoprazole (L15) and Omeprazole (O10)
Number of subjects: 20
Study: 18482486

Group type: EXPERIMENTAL
Intervention: GP intervention group (IG)
Number of subjects: 209

Group type: COMPARATOR
Intervention: Usual care control group 1 (CG1)
Number of subjects: 209

Group type: COMPARATOR
Intervention: Usual care control group 2 (CG2)
Number of subjects: 209
Study: 16167679

Group type: EXPERIMENTAL
Intervention: Nasal washing using a 30ml ear‐syringe bulb (NWb)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Nasopharyngeal aspiration (NPA)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Nasal washing using a 5ml syringe (NWs)
Number of subjects: 200
Study: 11744900

Group type: EXPERIMENTAL
Intervention: Standard anterior colporrhaphy
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Standard plus polyglactin 910 mesh
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Ultralateral anterior colporrhaphy
Number of subjects: 114

Group type: COMPARATOR
Intervention: All techniques
Number of subjects: 114
Study: 8978585

Group type: EXPERIMENTAL
Intervention: ondansetron 8 mg i.v. plus dexamethasone 20 mg i.v.
Number of subjects: 189

Group type: COMPARATOR
Intervention: metoclopramide 60 mg i.v. plus dexamethasone 20 mg i.v.
Number of subjects: 189
Study: 8496210

Group type: EXPERIMENTAL
Intervention: Arthroscopic subacromial decompression and rotator-cuff debridement
Number of subjects: 45

Group type: COMPARATOR
Intervention: Open repair and acromioplasty
Number of subjects: 45
Study: 2906344

Group type: EXPERIMENTAL
Intervention: Triphasic gestodene/ethinyl estradiol
Number of subjects: 120

Group type: COMPARATOR
Intervention: Triphasic levonorgestrel/ethinyl estradiol
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Monophasic gestodene/ethinyl estradiol
Number of subjects: 120

Group type: COMPARATOR
Intervention: Monophasic desogestrel/ethinyl estradiol
Number of subjects: 120
Study: 30840530

Group type: EXPERIMENTAL
Intervention: Cooling vest (VEST)
Number of subjects: 12

Group type: COMPARATOR
Intervention: CONTROL
Number of subjects: 12
Study: 28605286

Group type: EXPERIMENTAL
Intervention: Glargine U300
Number of subjects: 22

Group type: COMPARATOR
Intervention: Glargine U100
Number of subjects: 22
Study: 26021996

Group type: EXPERIMENTAL
Intervention: Ribavirin
Number of subjects: 0
Study: 25632615

Group type: EXPERIMENTAL
Intervention: Sublingual misoprostol (400 microg, two hours prior to MVA)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Oral misoprostol (400 microg, two hours prior to MVA)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Both groups (Sublingual and Oral)
Number of subjects: 80
Study: 21277628

Group type: EXPERIMENTAL
Intervention: 20 μg ZEA/kg bw for 48 days
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 40 μg ZEA/kg bw for 48 days
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo for 48 days
Number of subjects: 12
Study: 19217817

Group type: EXPERIMENTAL
Intervention: Strength training (twice weekly for 15 weeks followed by 24 weeks of unsupervised training)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 58
Study: 17196811

Group type: EXPERIMENTAL
Intervention: Lactobacillus GG (LGG)
Number of subjects: 141

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: All athletes (combined LGG and placebo)
Number of subjects: 141
Study: 14693613

Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.5% 200 mg/40 mL infiltrated at the wound site and continuous infusion of ropivacaine 0.2% at 5 mL/h for 55 hours
Number of subjects: 38

Group type: COMPARATOR
Intervention: Saline infusion at the same rate as the R group
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Ropivacaine continuous wound instillation
Number of subjects: 38
Study: 11339491

Group type: EXPERIMENTAL
Intervention: 80% age‐predicted maximal heart rate reserve (HRR)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 50% age‐predicted maximal heart rate reserve (HRR)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Attention control
Number of subjects: 24
Study: 9152189

Group type: EXPERIMENTAL
Intervention: Sodium phosphate (NaP)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Polyethylene glycol (PEG)
Number of subjects: 200
Study: 8239794

Group type: EXPERIMENTAL
Intervention: Warm antegrade blood cardioplegia
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Warm retrograde blood cardioplegia
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Cold antegrade blood cardioplegia
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Cold retrograde blood cardioplegia
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Intermittent cold antegrade blood cardioplegia
Number of subjects: 107

Group type: COMPARATOR
Intervention: Cold cardioplegia (general)
Number of subjects: 107
Study: 3322480

Group type: EXPERIMENTAL
Intervention: Anorectal myectomy
Number of subjects: 23

Group type: COMPARATOR
Intervention: Anal dilatation
Number of subjects: 23
Study: 30211001

Group type: EXPERIMENTAL
Intervention: Moderate-to-high intensity aerobic exercise for 16 weeks
Number of subjects: 51

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 51
Study: 27998386

Group type: EXPERIMENTAL
Intervention: Community-based intervention to reduce heat-related illness
Number of subjects: 4556

Group type: EXPERIMENTAL
Intervention: Community-based intervention
Number of subjects: 4556
Study: 24917049

Group type: EXPERIMENTAL
Intervention: Patella Pro brace with supervised physiotherapy
Number of subjects: 156

Group type: COMPARATOR
Intervention: Supervised physiotherapy alone
Number of subjects: 156
Study: 22429066

Group type: EXPERIMENTAL
Intervention: Milnacipran 100 mg/day continued
Number of subjects: 715

Group type: COMPARATOR
Intervention: Placebo (after switching from milnacipran)
Number of subjects: 715

Group type: EXPERIMENTAL
Intervention: Milnacipran 100 mg/day discontinued
Number of subjects: 715
Study: 19804497

Group type: EXPERIMENTAL
Intervention: Imiquimod 5% cream (group A)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Cryotherapy (group B)
Number of subjects: 74
Study: 18477073

Group type: EXPERIMENTAL
Intervention: Pre-operative oral carbohydrate drink (400 ml, 2 hours before surgery)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Pre-operative oral carbohydrate drink
Number of subjects: 101

Group type: COMPARATOR
Intervention: Control group (no drink given)
Number of subjects: 101
Study: 16159645

Group type: EXPERIMENTAL
Intervention: DTaP vaccination at 16 or 36 weeks after initiation of HAART
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: DTaP vaccination
Number of subjects: 37
Study: 11966737

Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) replacement therapy
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 10194013

Group type: EXPERIMENTAL
Intervention: Cruciate 4-strand repairs
Number of subjects: 40

Group type: COMPARATOR
Intervention: Kessler, Strickland, and Savage repairs
Number of subjects: 40
Study: 7670695

Group type: EXPERIMENTAL
Intervention: Lipid-lowering therapy
Number of subjects: 0
Study: 2180659

Group type: EXPERIMENTAL
Intervention: Experimental group using an algorithm for adjustment of insulin dosage based on daily prebreakfast capillary blood glucose measurements
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 53
Study: 575318

Group type: EXPERIMENTAL
Intervention: Bromocriptine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: PMT group
Number of subjects: 20
Study: 31288266

Group type: EXPERIMENTAL
Intervention: Zip device
Number of subjects: 25

Group type: COMPARATOR
Intervention: Staples
Number of subjects: 25
Study: 31046870

Group type: EXPERIMENTAL
Intervention: Endoscopic assisted powered adenoidectomy
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conventional curettage adenoidectomy
Number of subjects: 50
Study: 28762645

Group type: EXPERIMENTAL
Intervention: AHA-Ret Overnight Cream (double-conjugate retinoid cream)
Number of subjects: 48
Study: 25884390

Group type: EXPERIMENTAL
Intervention: DHEA 75 mg once a day
Number of subjects: 109

Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 109
Study: 23712970

Group type: EXPERIMENTAL
Intervention: Weight loss diets with 20% fat, 15% protein, 65% carbohydrates
Number of subjects: 710

Group type: EXPERIMENTAL
Intervention: Weight loss diets with 20% fat, 25% protein, 55% carbohydrates
Number of subjects: 710

Group type: EXPERIMENTAL
Intervention: Weight loss diets with 40% fat, 15% protein, 45% carbohydrates
Number of subjects: 710

Group type: EXPERIMENTAL
Intervention: Weight loss diets with 40% fat, 25% protein, 35% carbohydrates
Number of subjects: 710
Study: 21988544

Group type: EXPERIMENTAL
Intervention: Behavioral Activation Treatment for Depression (BATD)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Problem-Solving Therapy
Number of subjects: 80
Study: 19640508

Group type: EXPERIMENTAL
Intervention: Oxytocin
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study: 17280527

Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) replacement therapy, initially 2 microg/kg body weight/d, increased to a maximum of 12 microg/kg/d over 2 years.
Number of subjects: 67

Group type: COMPARATOR
Intervention: Placebo treatment.
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) replacement therapy in men.
Number of subjects: 67

Group type: COMPARATOR
Intervention: Placebo treatment in men.
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) replacement therapy in women.
Number of subjects: 67

Group type: COMPARATOR
Intervention: Placebo treatment in women.
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) replacement therapy.
Number of subjects: 67
Study: 15491239

Group type: EXPERIMENTAL
Intervention: Paroxetine CR 12.5 mg
Number of subjects: 447

Group type: EXPERIMENTAL
Intervention: Paroxetine CR 25 mg
Number of subjects: 447

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 447
Study: 11575340

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.2‐2.5 microg kg(‐1) h(‐1)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Propofol 1‐3 mg kg(‐1) h(‐1)
Number of subjects: 20
Study: 9650878

Group type: EXPERIMENTAL
Intervention: PDGF-BB pre-treated dentine surface (group 2)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Combination of PDGF-BB and IGF-1 pre-treated dentine surface (group 4)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: PDGF-BB treated TTC conditioned dentine surface (group 6)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: IGF-1 pre-treated dentine surface (group 3)
Number of subjects: 80

Group type: COMPARATOR
Intervention: TTC conditioned dentine surfaces (group 5)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: TTC conditioned dentine surfaces treated with IGF-1 (group 7)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: TTC conditioned dentine surfaces treated with combination of PDGF-BB and IGF-1 (group 8)
Number of subjects: 80
Study: 8595787

Group type: EXPERIMENTAL
Intervention: Tiagabine (TGB)
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1000
Study: 2649987

Group type: EXPERIMENTAL
Intervention: Ifosfamide
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: PVB (cisplatin, vinblastine, bleomycin) plus ifosfamide
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Ifosfamide-containing regimens
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Cisplatin, etoposide, and ifosfamide combination
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Ifosfamide in first-line treatment
Number of subjects: 203